Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Walz, Juliane
BeliVeR, NCT05069051: Belimumab in Patients with Chronic Lymphocytic Leukemia	Active, not recruiting	2	120	Europe	Belimumab 200 MG/ML [Benlysta], standard of care	University Hospital Tuebingen, GlaxoSmithKline	Chronic Lymphoid Leukemia in Relapse	07/26	07/27
NCT04496674: Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung	Terminated	1/2	3	Europe	CC-1 and Toczilizumab	German Cancer Research Center, University Hospital Tuebingen	Lung Cancer Squamous Cell	05/23	05/23
DKTK_PMO_1605, NCT04104607: The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma	Recruiting	1	86	Europe	CC-1, PSMAxCD3	University Hospital Tuebingen, German Cancer Research Center	Castration-Resistant Prostatic Cancer	12/25	12/25
iVAC-XS15-CLL01, NCT04688385: Personalized Multi-peptide Vaccination in CLL Patients	Completed	1	20	Europe	Multipeptide Vaccine+ XS15	University Hospital Tuebingen	Chronic Lymphocytic Leukemia	10/24	10/24
FusionVAC22, NCT05937295: _01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition	Recruiting	1	20	Europe	Fusion-VAC-XS15	University Hospital Tuebingen	Fibrolamellar Hepatocellular Carcinoma	09/26	01/27
InHeAb01, NCT05119257: (Bispecific) Antibodies in Cancer Patients	Available	N/A		Europe	Bispecific antibodies (bsAB)	University Hospital Tuebingen	Cancer